TLSAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (21 5月 2024 @ 23:52):

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology...

Stats
本日の出来高	75 407.00
平均出来高	198 846
時価総額	82.02M
EPS	$0 ( 2024-04-22 )
次の収益日	( $0 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.68
ATR14	$0.0100 (1.26%)

ボリューム相関

長: 0.25 (neutral)

短: -0.27 (neutral)

Signal:(51.816) Neutral

Tiziana Life Sciences PLC 相関

10 最も正の相関

10 最も負の相関
FITBP	-0.876
ACGLN	-0.87
PFF	-0.853
ENLV	-0.842
RCEL	-0.838
JSM	-0.837
ADSK	-0.827
FITBO	-0.814
FTXH	-0.811
BJK	-0.806

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Tiziana Life Sciences PLC 相関 - 通貨/商品

0.31
( neutral )

0.44
( neutral )

0.00
( neutral )

0.58
( weak )

0.00
( neutral )

-0.61
( weak negative )

Tiziana Life Sciences PLC 財務諸表

Annual	2022
収益:	$0
総利益:	$-51 000.00 (0.00 %)
EPS:	$-0.160

FY	2022
収益:	$0
総利益:	$-51 000.00 (0.00 %)
EPS:	$-0.160

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.139

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.120

Financial Reports:

No articles found.

Tiziana Life Sciences PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Tiziana Life Sciences PLC

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.